# Treating Hepatitis C with Combination Drug Therapy

> A Gilead Sciences patent detailing a method to treat Hepatitis C by combining a specific chemical compound with an NS5a inhibitor.

- **Patent:** US 8735372
- **Original title:** Nucleoside phosphoramidate prodrugs
- **Owner:** Gilead Pharmasset LLC
- **Granted:** 2014
- **Status:** Active
- **Times cited:** 42
- **Field:** biotech, pharmaceutical

## What it does

This patent describes a medical treatment for Hepatitis C that uses a two-part drug strategy. It requires the administration of an NS5a inhibitor alongside a specific type of chemical compound known as a nucleoside phosphoramidate prodrug. The patent defines the precise molecular structure of this prodrug, including various side chains and chemical groups that allow the drug to be effective. By combining these two distinct types of inhibitors, the treatment aims to disrupt the Hepatitis C virus's ability to replicate in the human body.

## What it does NOT cover

- Does not cover the use of the phosphoramidate prodrugs as a standalone treatment.
- Does not cover chemical structures that fall outside the specific R1, R2, R3, R4, R7, and R8 substituent definitions provided.
- Does not cover treatments for viral infections other than Hepatitis C.
- Does not cover the synthesis of the NS5a inhibitor itself.

## The clever bit

The innovation lies in using a 'prodrug'—a biologically inactive compound that the body converts into the active medicine—specifically designed to bypass the rate-limiting step of drug activation inside the liver cells, which was a major hurdle for earlier nucleoside-based antivirals.

## Real-world examples

1. Sovaldi (sofosbuvir)
2. Harvoni (ledipasvir/sofosbuvir)

## Why it matters

This patent is central to the development of highly effective direct-acting antivirals for Hepatitis C. It represents the shift toward combination therapies that have made Hepatitis C a curable disease rather than a chronic, lifelong condition. The technology is foundational to the commercial success of blockbuster drugs like Sovaldi and Harvoni.

## Frequently asked questions

### What does Treating Hepatitis C with Combination Drug Therapy cover?

A Gilead Sciences patent detailing a method to treat Hepatitis C by combining a specific chemical compound with an NS5a inhibitor.

### Who owns patent US 8735372?

Gilead Pharmasset LLC owns this patent, granted in 2014.

### When does this patent expire?

This patent is expected to expire on May 27, 2034, when the invention enters the public domain.

### What is patent US 8735372 cited by?

This patent has been cited by 42 later patents that build on its ideas.

### What problem does this patent solve?

This patent is central to the development of highly effective direct-acting antivirals for Hepatitis C. It represents the shift toward combination therapies that have made Hepatitis C a curable disease rather than a chronic, lifelong condition. The technology is foundational to the commercial success of blockbuster drugs like Sovaldi and Harvoni.

### What does this patent NOT cover?

Does not cover the use of the phosphoramidate prodrugs as a standalone treatment.

**Full plain-English explainer:** https://patentbrief.org/patent/us/8735372/sovaldi-sofosbuvir-composition

**Original patent:** https://patents.google.com/patent/US8735372

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._